The Galien Foundation recently announced the nominees for the 2024 Prix Galien International Awards, with categories including: "Best Biotechnology Product," "Best Digital Health Solution," "Most Innovative Medical Device," "Best Pharmaceutical Product," and "Best Orphan/Rare Disease Product."
(Image source: official)
The Galien International Award (Prix Galien International Awards) is an international honor presented once every two years. Nominees must have won a national Galien Award (such as the Prix Galien USA Awards, Prix Galien UK Awards, etc.) within the past two years. This also means that this year's most innovative medical device winner will be the best innovative product globally from 2022 and 2023.
A total of 9 innovative medical device products have been nominated for the Most Innovative Medical Device award:
Cala kIQCala kIQ is an innovative wearable device used to treat hand tremors in patients with essential tremor and Parkinson's disease.Cala kIQ provides patients with a non-invasive treatment option as an alternative to traditional medications or even surgery, offering high safety and minimal side effects. Its system utilizes Cala TAPS therapy, which has been validated through large-scale clinical studies and real-world evidence, demonstrating significant tremor reduction and improved ability in activities of daily living (ADLs).CERENOVUS's EmboTrap® III Revascularization Device is a cutting-edge thrombectomy stent introduced by Johnson & Johnson, representing the advanced technology currently available on the market for the treatment of Acute Ischemic Stroke (AIS).
This device adopts an innovative double-layer, segmented design, enabling it to efficiently capture and remove thrombi. Its distal-closing double-layer mesh basket thrombectomy stent design features a unique distal-closing structure, a double-layer mesh open-loop design, and clear stent visibility, which help improve the success rate of the procedure.
Double-layer Basket Design: One of the core design features of EmboTrap® III is its double-layer basket structure, which helps to more effectively capture and remove thrombus during thrombectomy procedures.Distal Closure Structure: The distal closure design of this device means it can better seal at the far end of the blood vessel, thereby reducing the possibility of thrombus fragments escaping to the distal end of the vessel, which helps to lower the risk of distal embolism.Endotest is an innovative non-invasive medical diagnostic device used for the early diagnosis of endometriosis. It detects endometriosis by analyzing microRNAs (miRNAs) in saliva samples and utilizes artificial intelligence (AI) technology to enhance the accuracy of detection.
Endotest is a simple, rapid, and reliable diagnostic tool capable of diagnosing all types of endometriosis with near 100% high reliability (sensitivity >95%, specificity >95%, diagnostic accuracy AUC >95%).
Cyted Health's EndoSign® is an innovative non-endoscopic capsule sponge test technology used to detect Barrett's esophagus (a precancerous lesion of esophageal cancer).
EndoSign consists of two parts: a swallowable capsule and a laboratory test used to analyze the collected cell samples. The EndoSign capsule is a small, swallowable device containing a sponge-like substance inside. This sponge is released when the capsule reaches a specific location in the esophagus and adheres to the esophageal wall. The sponge is designed to effectively collect cell samples from the surface of the esophagus.Boston Scientific's FARAPULSE™ Pulsed Field Ablation System is an innovative medical device used to treat drug-refractory, recurrent symptomatic paroxysmal atrial fibrillation. The entire system includes the Farawave ablation catheter, Farastar ablation generator, and Faradrive steerable sheath, collectively delivering pulsed field energy.
FARAWAVE™ Ablation Catheter: A 12Fr diameter ablation catheter with a flower-shaped design at its distal end, consisting of 5 "petals," each equipped with 4 electrodes. The distal end can be controlled to be either in the "bud" or "full bloom" configuration via a slider button on the handle.
FARASTAR™ Ablation Generator: Utilizes bipolar and biphasic waveforms along with proprietary pulses; simple interface operation allows for isolation of a pulmonary vein vestibule using just three buttons.
FARADRIVE™ Steerable Sheath: A 13Fr distal steerable sheath designed to better navigate FARAWAVE to the ostia of each pulmonary vein.
Guardant Health's Guardant360 CDx is a liquid biopsy test based on next-generation sequencing (NGS) technology. It provides oncologists with crucial genomic information by analyzing circulating tumor DNA (ctDNA) in blood samples. As the first comprehensive liquid biopsy to receive FDA approval, Guardant360 CDx is particularly suited for tumor mutation profiling in patients with advanced cancer.This test requires only two tubes of blood samples and can provide results within 7 days, covering more than 70 gene mutations related to various solid tumors. It has demonstrated high consistency with tissue testing in multiple prospective studies, ensuring the speed and accuracy of the detection.
Synergia Medical's NAO.VNS is an innovative device for the treatment of drug-resistant epilepsy. It is the world’s first neurostimulator to use quartz optoelectronic technology, reducing and stopping epileptic seizures through vagus nerve stimulation (VNS). This new type of neurostimulator leverages advanced material technology to improve patients' quality of life.The unique design of NAO.VNS allows it to be safely used during functional magnetic resonance imaging (fMRI) scans, enabling the device’s performance to be evaluated and optimized at the time of implantation. It is powered by a rechargeable battery, extending the device's lifespan and allowing for continuous collection of patient data through dedicated biomarkers.
Coloplast's Peristeen® Plus is a medical device used for bowel management, specifically designed for patients with neurogenic bowel dysfunction.
Peristeen® Plus introduces water into the rectum through a rectal catheter, helping to flush and promote the evacuation of lower colon contents. When used daily or every other day as directed by a healthcare professional, this technique can assist users in maintaining bowel control for up to 48 hours.
The Peristeen® Plus system includes a control unit, a water bag with a temperature indicator, two straps, a tube, etc. This system is easy to carry and store, and only requires the use of tap water. Peristeen® Plus can be operated by the patient independently or with the assistance of others, allowing users to decide for themselves when and where to evacuate bowel contents.
Sonio's Sonio Diagnostics is an AI-driven prenatal screening and diagnostic software that combines medical imaging, genetic, and environmental data to provide healthcare providers with secure prenatal care. Founded in 2020 by Cecile Brosset and Remi Besson, the software integrates technological innovation, medical expertise, and collective intelligence.
A notable feature of Sonio Detect is its ability to accelerate the identification of critical anatomical structures, such as the heart and brain, during fetal ultrasound. This not only saves valuable time for healthcare professionals but also increases confidence in the diagnostic process. Additionally, Sonio Diagnostics possesses a database covering 250 symptoms and 700 abnormalities, enabling healthcare professionals to make informed decisions and provide timely interventions.▲ Source: Medical Device Innovation Network▲Please indicate the source above when reprintingDisclaimer: This article is intended solely for the purpose of information transmission and is for reference only. It does not constitute any advice on investment or treatment; please evaluate carefully. If it involves issues related to the content, copyright, or other aspects of the work, to ensure the rights and interests of both parties, please contact us and we will handle it immediately. If any platform reprints this article, it must take responsibility for the content of the article itself. The Medical Device Innovation Network is not responsible for any secondary dissemination caused by reprints.
